Introduction
Contrast-induced nephropathy (CIN) is a commonly occurring complication associated with the use of contrast media in various diagnostic and interventional radiological studies. Recently, it has been suggested that statins have a possible beneficial effect in limiting CIN occurrence [1] . In fact, in addition to their intended impact on blood cholesterol levels, statins have been found to have multiple nonlipid-lowering (pleiotropic) effects that might contribute to the decrease of cardiovascular morbidity and mortality [2] , particularly in patients with chronic kidney disease (CKD) [reducing the relative risk of major cardiovascular events by 32% in patients with CKD (hazard ratio ¼ 0.68; 95% CI 0.55-0.84; P ¼ 0.0003) and 15% in patients with normal estimated glomerular filtration rate (eGFR)] [3]. The pleiotropic effects include enhancement of endothelial nitric oxide production [4] [5] [6] , inhibition of smooth muscle proliferation [7] , and anti-inflammatory and antioxidative actions [8, 9] . Given their anti-inflammatory, antioxidant and antithrombotic properties, statins could decrease acute iatrogenic renal injury after iodinated contrast administration due to their influence on inflammatory mechanisms, oxidative stress and endothelial function [4] . Khanal et al. [10] , in a retrospective study that evaluated a large cohort of patients who underwent percutaneous coronary interventions (PCIs), showed that patients on chronic statin therapy before the procedure had a significantly lower incidence of CIN; the benefit of previous continuous statin use was consistent in all creatinine clearance categories of patients. In a later prospective, nonrandomized study, Patti et al. [11] observed an early protective effect against CIN occurrence in cases of long-term statin therapy. The PROMISS (Prevention of radiocontrast-medium-induced nephropathy using short term high-dose simvastatin) study was the first randomized prospective trial focused on the role of short-term simvastatin therapy as a specific prophylactic measure of CIN prevention regardless of patient lipid profile [12] . The results of this study showed that short-term simvastatin pretreatment (48 h) at high dose (40 mg twice daily) does not prevent renal function deterioration after administration of contrast medium in patients with baseline renal insufficiency undergoing coronary angiography. In this article we review the clinical studies and trials performed to elucidate this subject in the past year (Table 1) .
Review
Early in 2010, Toso et al. [13 ] reported the efficacy of high-dose atorvastatin in preventing CIN in CKD patients. It was a prospective, randomized, placebocontrolled trial performed in 304 patients with baseline CKD undergoing elective coronary angiography and/or other intervention. One hundred and fifty-two patients were assigned to receive high doses of atorvastatin (80 mg/day) and 152 to receive matching placebo for 48 h before and 48 h after contrast medium administration. All patients received intravenous standard hydration with isotonic saline and N-acetylcysteine (NAC) 1200 mg twice daily, from the day before to the day after the procedure. Nonionic, iso-osmolar contrast medium (Iodixanol; Visipaque, GE Healthcare Ltd., Amersham, UK) was used. CIN was defined as an absolute increase of serum creatinine of at least 0.5 mg/dl within 5 days of the procedure. CIN occurred in 10% (n ¼ 31) of patients, 11% (n ¼ 16) in the placebo group and 10% (n ¼ 15) in the atorvastatin group (P ¼ 0.86). Mean increase in serum creatinine was not significantly different in the two groups (P ¼ 0.31). Persistent kidney injury, defined as a 1-month increase from baseline creatinine value of at least 25%, was observed in 30% in the placebo group vs. 31% in the treatment group (P ¼ 0.58). The authors concluded that a short-term administration of high-dose atorvastatin before and after contrast exposure, in addition to standard intravenous hydration and oral NAC, does not decrease CIN occurrence in patients with pre-existing CKD. These results confirmed and extend the relevance of PROMISS data showing that, in patients with moderate to severe CKD, short-term use of atorvastatin before and after contrast procedure did not further decrease CIN occurrence when added to intravenous hydration and oral NAC [12] . Moreover, the study population was at higher risk for CIN than the PROMISS population because the participants were older, had lower baseline estimated creatinine clearance, lower ejection fraction and a higher incidence of PCI. All these could explain the higher incidence of CIN in this study (10%) compared with the PROMISS study (2.5%). An important limitation of this study was that the authors did not test the effect of statin therapy in a parallel group of patients not pretreated with oral NAC. Second, short duration of treatment with statin would not have been sufficient for it to have nephroprotective effect. The persistence of contrast beyond 48 h would have contributed, as statins were given for only 48 h. It is possible that statin treatment longer than 7 days might have beneficial effects against the development of CIN.
In another trial, 130 patients were randomized to shortterm, high-dose atorvastatin (80 mg twice daily) and NAC (600 mg twice daily) on the first day, followed by 80 mg atorvastatin for 2 days after the procedure or NAC only (600 mg twice daily) on the first day [14 ] . All patients were hydrated with standard 1 l normal saline infusion for 6 h after the procedure. CIN was defined as a postprocedural increase in serum creatinine of greater than 0.5 mg/dl or 25% from baseline within 48 h of contrast administration. Patients with renal insufficiency (defined as preprocedural serum creatinine >1.5 mg/dl) or eGFR below 70 ml/min (calculated using the Cockcroft-Gault formula) were excluded. Seven patients (10%) developed CIN in the NAC-only group compared with two cases (3.33%) in the statin and NAC group. Baseline serum creatinine and eGFR were comparable between the two groups, whereas after the procedure there was a significant creatinine decrease (P ¼ 0.03) and eGFR (P ¼ 0.03) increase in the atorvastatin and NAC group. Similar beneficial effects of statins have previously been demonstrated by Patti et al. [11] , who conducted a prospective study on 430 patients (260 statin-treated and 174 statinnaive) and followed them for 4 years. Statin-treated patients had a significantly lower incidence of CIN (3 vs. 27%; P < 0.0001) and a better postprocedural creatinine clearance (P < 0.0001). During follow-up, CIN was
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Key points
Contrast-induced nephropathy is a commonly occurring complication associated with the use of contrast media in radiological studies. Various clinical studies have been reported investigating the nephroprotective role of statins. An overview of these indicates that the evidence for the use of statins specifically for offering renal protection against CIN is conflicting and inconclusive. Large, well designed, adequately powered randomized controlled trials are required to provide reliable evidence that statins can offer protection against contrast-induced nephropathy. None a predictor of poorer outcome; 4-year survival free of major adverse cardiac events was highest in statin-treated patients without CIN.
Kandula et al.
[15 ] retrospectively evaluated 353 patients who underwent nonemergency PCI over a 3-year period. CIN was defined as an increase of more than 25% or more than 44 mmol/l in baseline serum creatinine at 48-72 h following PCI. Two hundred and thirty-nine patients were taking statins before PCI and 114 were not. CIN occurred in 75 patients (21.2%). None of these patients required dialysis. There was a higher incidence of CIN in patients on statins as compared with patients not on statins (24.7 vs. 14%; P ¼ 0.02). However, propensitybased adjustment for receipt of statins revealed no significant differences in CIN between both groups (P ¼ 0.12). The authors concluded that statin use before nonemergency PCI is not associated with reduction in CIN. Mehran score was used to classify patients for the risk of development of CIN [17] . Multivariate logistic regression revealed Mehran score to be independently predictive of CIN. The above observations were, however, in contrast to the findings reported by Acikel et al. [16 ] . One hundred and sixty patients undergoing elective PCI were randomized into two groups: atorvastatin 40 mg/day group (statin started 3 days before PCI) and an untreated control group. An additional 80 patients were included as a chronic statin therapy group. Serum creatinine, serum cystatin C and GFR (calculated by Modification of Diet in Renal Disease) were measured before and 48 h after the PCI. Serum creatinine and GFR were observed to be significantly better in patients using atorvastatin than controls (P ¼ 0.002, P ¼ 0.004, respectively). Postprocedure serum creatinine, serum cystatin C and GFR were also significantly better in the chronic statin therapy group than in the control group (P ¼ 0.006, P ¼ 0.003 and P ¼ 0.004, respectively). No difference in renal function parameters between the short-term atorvastatin group and the chronic statin therapy group was observed. The results suggest that the use of short-term atorvastatin and chronic statin therapy may have a role to play in protecting renal function after elective coronary angiography.
Conclusion
An overview of the research studies reported in 2010 indicates that the evidence for the use of statins specifically for offering renal protection against CIN is conflicting and inconclusive, with some studies in favor of their use in reducing CIN, others not showing any relevant beneficial effects. The most likely reason for this has been diverse study populations, lack of adequate sample size and multifactorial cause of CIN. This conclusion is in accordance with a previous systematic review done by Beri et al. [18] which included trials performed until 2009. However, from the work of Fujita et al. [19] , which suggests that statins attenuate glomerulonephritis by inhibiting macrophage infiltration, and from the experience of using statin preloading in PCI to improve postprocedure outcomes, it can be speculated that statins potentially can provide nephroprotection against CIN [20] [21] [22] .
